Authors

• Susumu Suzuki (ORCID: https://orcid.org/0000-0002-1466-8824)
• Kazuhiro Kakimi (ORCID: https://orcid.org/0000-0003-2631-3040)
• Ryuzo Ueda (ORCID: https://orcid.org/0000-0003-1120-1142)
• Hiroyoshi Nishikawa (ORCID: https://orcid.org/0000-0001-6563-9807)
• Hisashi Wada (ORCID: https://orcid.org/0000-0002-5444-6193)
• Taishi Takahara (ORCID: https://orcid.org/0000-0001-9219-8357)
• Koichi Jinushi (ORCID: https://orcid.org/0000-0001-9888-2387)
• Tomoki Makino (ORCID: https://orcid.org/0000-0001-7918-4217)
• Takuro Saito (ORCID: https://orcid.org/0000-0002-1733-5064)
• Shinsuke Iida (ORCID: https://orcid.org/0000-0002-4951-960X)
• Takashi Kojima (ORCID: https://orcid.org/0000-0002-7226-3518)
• Tetsuya Ogawa
• Jun Nakajima (ORCID: https://orcid.org/0000-0003-1174-0816)
• Koji Kurose
• Mikio Oka (ORCID: https://orcid.org/0000-0002-7914-5768)
• Yuichiro Doki

Institutions

• Bunkyo University (JP)
• Osaka Prefecture University (JP)
• Aichi Medical University (JP)
• Kawasaki Medical School (JP)
• Nagoya City University (JP)
• National Cancer Centre Japan (JP)
• Aichi Medical University Hospital (JP)
• University of Tokyo Hospital (JP)
• Immunité et Cancer (FR)
• National Cancer Center Hospital East (JP)
• National Cancer Research Institute (GB)
• Nagoya University (JP)
• The University of Tokyo (JP)
• Kindai University (JP)
• The University of Osaka (JP)

Publication Details

Journal

Journal for ImmunoTherapy of Cancer

Published

2025-04-01

DOI

https://doi.org/10.1136/jitc-2024-010634

Citations

5

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

5.23

Funders

• Japan Agency for Medical Research and Development
• Ministry of Education, Culture, Sports, Science and Technology
• Kyowa Hakko Kirin
• Ono Pharmaceutical